Comparison of baseline patient characteristics and functional PET parameters in the testing (N = 141) and validation (N = 113) cohorts
| Clinical features . | Testing set (SAKK 38/07), n (%) . | Validation set, n (%) . | P* . |
|---|---|---|---|
| Sex | .833 | ||
| Male | 73 (52) | 57 (51) | |
| Female | 68 (48) | 56 (49) | |
| Age | |||
| Median; IQR | 59 y; 49-68 | 70 y; 57-76 | <.0001 |
| >60 y | 68 (48) | 80 (71) | <.0001 |
| Ann Arbor stage | .275 | ||
| 1 | 15 (11) | 15 (13) | |
| 2 | 46 (33) | 34 (30) | |
| 3 | 33 (23) | 17 (15) | |
| 4 | 47 (33) | 47 (42) | |
| Bulky disease | |||
| >7.5 cm | 70 (50) | 50 (44) | .392 |
| >10 cm | 42(30) | 29 (26) | .375 |
| Elevated LDH | 68 (48) | 56 (50) | .726 |
| ECOG PS >1 | 10 (7) | 9 (8) | .793 |
| Extranodal sites >1 | 34 (24) | 25 (22) | .709 |
| COO (Hans algorithm) | N = 113 | N = 99 | <.001 |
| GCB | 29 (26) | 58 (59) | |
| Non-GCB | 84 (74) | 41 (41) | |
| IPI group | .085 | ||
| Low risk | 65 (46) | 36 (32) | |
| Intermediate-low risk | 32 (23) | 39 (34) | |
| Intermediate-high risk | 27 (19) | 25 (22) | |
| High risk | 17 (12) | 13 (12) | |
| R-IPI group | .111 | ||
| Low risk | 22 (16) | 8 (7) | |
| Intermediate risk | 75 (53) | 67 (59) | |
| High risk | 44 (31) | 38 (34) | |
| NCCN-IPI group | .007 | ||
| Low risk | 22 (16) | 7 (6) | |
| Intermediate-low risk | 67 (47) | 42 (37) | |
| Intermediate-high risk | 39 (28) | 51 (45) | |
| High risk | 13 (9) | 13 (12) | |
| PET parameters, median (IQR) | |||
| SUVmax | 19.9 (15.1-28.2) | 21 (13.5−28.1) | .95 |
| MTV | 386 (143-1119) | 342 (78- 822) | .12 |
| TLG | 2618 (824-8906) | 2325 (472-5390) | .08 |
| Metabolic heterogeneity (AUC-CSH) | 0.45 (0.40-0.50) | 0.49 (0.46-0.53) | <.001 |
| Clinical features . | Testing set (SAKK 38/07), n (%) . | Validation set, n (%) . | P* . |
|---|---|---|---|
| Sex | .833 | ||
| Male | 73 (52) | 57 (51) | |
| Female | 68 (48) | 56 (49) | |
| Age | |||
| Median; IQR | 59 y; 49-68 | 70 y; 57-76 | <.0001 |
| >60 y | 68 (48) | 80 (71) | <.0001 |
| Ann Arbor stage | .275 | ||
| 1 | 15 (11) | 15 (13) | |
| 2 | 46 (33) | 34 (30) | |
| 3 | 33 (23) | 17 (15) | |
| 4 | 47 (33) | 47 (42) | |
| Bulky disease | |||
| >7.5 cm | 70 (50) | 50 (44) | .392 |
| >10 cm | 42(30) | 29 (26) | .375 |
| Elevated LDH | 68 (48) | 56 (50) | .726 |
| ECOG PS >1 | 10 (7) | 9 (8) | .793 |
| Extranodal sites >1 | 34 (24) | 25 (22) | .709 |
| COO (Hans algorithm) | N = 113 | N = 99 | <.001 |
| GCB | 29 (26) | 58 (59) | |
| Non-GCB | 84 (74) | 41 (41) | |
| IPI group | .085 | ||
| Low risk | 65 (46) | 36 (32) | |
| Intermediate-low risk | 32 (23) | 39 (34) | |
| Intermediate-high risk | 27 (19) | 25 (22) | |
| High risk | 17 (12) | 13 (12) | |
| R-IPI group | .111 | ||
| Low risk | 22 (16) | 8 (7) | |
| Intermediate risk | 75 (53) | 67 (59) | |
| High risk | 44 (31) | 38 (34) | |
| NCCN-IPI group | .007 | ||
| Low risk | 22 (16) | 7 (6) | |
| Intermediate-low risk | 67 (47) | 42 (37) | |
| Intermediate-high risk | 39 (28) | 51 (45) | |
| High risk | 13 (9) | 13 (12) | |
| PET parameters, median (IQR) | |||
| SUVmax | 19.9 (15.1-28.2) | 21 (13.5−28.1) | .95 |
| MTV | 386 (143-1119) | 342 (78- 822) | .12 |
| TLG | 2618 (824-8906) | 2325 (472-5390) | .08 |
| Metabolic heterogeneity (AUC-CSH) | 0.45 (0.40-0.50) | 0.49 (0.46-0.53) | <.001 |
Bold P values indicate statistically significant results (P < .05).
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
χ2 test for comparison of frequencies and Mann-Whitney U test for comparison of medians.